Emicizumab was approved as a first-line therapy for severe bleeding disorders in 2017. According to a study, infants with hemophilia A who received monoclonal antibody emicizumab experienced few bleeding events and no serious complications.
Join the Alumni Association and get a treat from Zingerman’s
